Aimmune Therapeutics Inc. [NASDAQ: AIMT] stock went on a downward path that fall over -0.09% on Wednesday, amounting to a one-week price decrease of less than -0.07%.
Over the last 12 months, AIMT stock rose by 57.68%. The one-year Aimmune Therapeutics Inc. stock forecast points to a potential downside of -2.88. The average equity rating for AIMT stock is currently 2.60, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.24 billion, with 65.18 million shares outstanding and 50.98 million shares in the current float. Compared to the average trading volume of 2.08M shares, AIMT stock reached a trading volume of 2183451 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Aimmune Therapeutics Inc. [AIMT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AIMT shares is $33.32 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AIMT stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for Aimmune Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 13, 2020. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $30 to $15. The new note on the price target was released on May 12, 2020, representing the official price target for Aimmune Therapeutics Inc. stock. On February 28, 2020, analysts decreased their price target for AIMT shares from 33 to 30.
The Average True Range (ATR) for Aimmune Therapeutics Inc. is set at 0.77, with the Price to Sales ratio for AIMT stock in the period of the last 12 months amounting to 3738.23. The Price to Book ratio for the last quarter was 12.42, with the Price to Cash per share for the same quarter was set at 4.80.
AIMT Stock Performance Analysis:
Aimmune Therapeutics Inc. [AIMT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.07. With this latest performance, AIMT shares gained by 174.68% in over the last four-week period, additionally plugging by 147.51% over the last 6 months – not to mention a rise of 57.68% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AIMT stock in for the last two-week period is set at 88.90, with the RSI for the last a single of trading hit 91.65, and the three-weeks RSI is set at 84.72 for Aimmune Therapeutics Inc. [AIMT]. The present Moving Average for the last 50 days of trading for this stock 20.88, while it was recorded at 34.30 for the last single week of trading, and 21.78 for the last 200 days.
Insight into Aimmune Therapeutics Inc. Fundamentals:
Return on Total Capital for AIMT is now -109.36, given the latest momentum, and Return on Invested Capital for the company is -109.33. Return on Equity for this stock declined to -123.33, with Return on Assets sitting at -91.37. When it comes to the capital structure of this company, Aimmune Therapeutics Inc. [AIMT] has a Total Debt to Total Equity ratio set at 51.73. Additionally, AIMT Total Debt to Total Capital is recorded at 34.09, with Total Debt to Total Assets ending up at 26.33. Long-Term Debt to Equity for the company is recorded at 49.56, with the Long-Term Debt to Total Capital now at 32.66.
Reflecting on the efficiency of the workforce at the company, Aimmune Therapeutics Inc. [AIMT] managed to generate an average of -$903,625 per employee.Aimmune Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.40 and a Current Ratio set at 7.50.
AIMT Stock EPS
With the latest financial reports released by the company, Aimmune Therapeutics Inc. posted -1.03/share EPS, while the average EPS was predicted by analysts to be reported at -1.03/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AIMT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Aimmune Therapeutics Inc. go to 34.60%.
Aimmune Therapeutics Inc. [AIMT] Insider Position Details
There are presently around $1,730 million, or 87.20% of AIMT stock, in the hands of institutional investors. The top three institutional holders of AIMT stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 5,274,902, which is approximately 1.584% of the company’s market cap and around 0.90% of the total institutional ownership; VANGUARD GROUP INC, holding 4,202,544 shares of the stock with an approximate value of $144.06 million in AIMT stocks shares; and BLACKROCK INC., currently with $134.59 million in AIMT stock with ownership of nearly 8.159% of the company’s market capitalization.
97 institutional holders increased their position in Aimmune Therapeutics Inc. [NASDAQ:AIMT] by around 6,511,951 shares. Additionally, 60 investors decreased positions by around 5,688,202 shares, while 30 investors held positions by with 38,261,790 shares. The mentioned changes placed institutional holdings at 50,461,943 shares, according to the latest SEC report filing. AIMT stock had 25 new institutional investments in for a total of 1,831,892 shares, while 25 institutional investors sold positions of 967,766 shares during the same period.